Literature DB >> 8186298

Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors.

E J Boviatsis1, M Chase, M X Wei, T Tamiya, R K Hurford, N W Kowall, R I Tepper, X O Breakefield, E A Chiocca.   

Abstract

Three vectors derived from retrovirus, herpes simplex virus type 1 (HSV), and adenovirus were compared in cultured rat 9L gliosarcoma cells for gene transfer efficiency and in a 9L rat brain tumor model for histologic pattern and distribution of foreign gene delivery, as well as for associated tumor necrosis and inflammation. At a multiplicity of infection of 1, in vitro transfer of a foreign gene (lacZ from Escherichia coli) into cells was more efficient with either the replication-defective retrovirus vector or the replication-conditional thymidine kinase (TK)-deficient HSV vector than with the replication-defective adenovirus vector. In vivo, stereotactic injections of each vector into rat brain tumors revealed three main histopathologic findings: (i) retrovirus and HSV vector-mediated gene transfer was relatively selective for cells within the tumor, whereas adenovirus vector-mediated gene transfer occurred into several types of endogenous neural cells, as well as into cells within the tumor; (ii) gene transfer to multiple infiltrating tumor deposits without apparent gene transfer to intervening normal brain tissue occurred uniquely in one animal inoculated with the HSV vector, and (iii) extensive necrosis and selective inflammation in the tumor were evident with the HSV vector, whereas there was minimal evidence of tumor necrosis and inflammation with either the retrovirus or adenovirus vectors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186298     DOI: 10.1089/hum.1994.5.2-183

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

1.  Characterization of promoter function and cell-type-specific expression from viral vectors in the nervous system.

Authors:  R L Smith; D L Traul; J Schaack; G H Clayton; K J Staley; C L Wilcox
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 4.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Authors:  K Ikeda; H Wakimoto; T Ichikawa; S Jhung; F H Hochberg; D N Louis; E A Chiocca
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain.

Authors:  L L Muldoon; G Nilaver; R A Kroll; M A Pagel; X O Breakefield; E A Chiocca; B L Davidson; R Weissleder; E A Neuwelt
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 7.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

8.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

Authors:  J Fick; F G Barker; P Dazin; E M Westphale; E C Beyer; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.

Authors:  N M Carroll; E A Chiocca; K Takahashi; K K Tanabe
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

10.  In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.

Authors:  Jeong-Heum Baek; Munna L Agarwal; Raymond R Tubbs; Alex Vladisavljevic; Hiroshi Tomita; Ronald M Bukowski; Jeffrey W Milsom; Jin-Man Kim; Jin-Young Kwak
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.